An interventional study of Multimodality Imaging in Myocardial Infarction, Myocardial Injury and Myocardial Inflammation, sponsored by Wuerzburg University Hospital. Recruiting at 2 sites in Germany. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-05-25.
Sponsored by Wuerzburg University Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 159 studies in Myocardial Infarction with a site in Germany — 13 open to participants now, 17 under way, 5 of them phase 3. Myocardial Infarction · Germany.
Among the 159 studies in Myocardial Infarction with a site in Germany, this one is the 93rd largest by planned enrollment of the 107 interventional ones that give a count, is one of 4 that started in 2022, is one of 24 with no phase, reaches primary completion later than 1 of the 16 other live ones, and was the 143rd registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →13 of the 159 studies in Myocardial Infarction with a site in Germany are open now. Recruiting first, the newest first:
University Hospital of Cologne · Sites in Germany
Ages 18–77
University Hospital Freiburg · Sites in Germany
Ages 18–85
Medical University Innsbruck · Sites in Germany, Austria
Ages 18+
CSL Behring · Sites in Germany, United States, Argentina and 32 more countries
Ages 18+
Charite University, Berlin, Germany · Sites in Germany, Austria, Belgium and 10 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
159 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 21 · Phase 3 44 · Phase 4 20
First in 1994; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 57 is below the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 429 across the 107 interventional studies, 750 across the 51 observational. Of the 133 that completed or were terminated, 33 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 159 have an industry lead sponsor. The 10 most frequent:
Wuerzburg University Hospital is the lead sponsor of 98 studies on the registry; 19 are open to participants now.
Wuerzburg University Hospital has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
4 of the studies in Myocardial Infarction with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT07785921Kliniken Essen-MitteHealth Behaviour and Readiness to Change After Myocardial Infarction: A Cross-sectional Survey | 2027-03-30 |
| NCT05665608Charite University, Berlin, GermanyPrevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 159 studies in Myocardial Infarction with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The adaptive immune response plays an important role in myocardial healing and remodeling after acute myocardial infarction in patients. Therefore, the involved lymphocytes represent a novel target for therapeutic interventions. However, there are no established blood-derived biomarkers to predict the quantity and quality of the adaptive immune response to cardiac injury. Multimodal imaging of the heart and immunologic organs might provide such information.
Recent retrospective analysis of patients after MI revealed enlarged mediastinal lymph nodes associated with increased CXCR4 radiotracer accumulation, thereby indicating that CXCR4 PET-based lymph node imaging provides a non-invasive quantitative readout of the local adaptive immune response. These considerations are further fuelled by the fact that, within lymph nodes, CXCR4 is expressed almost exclusively on lymphocytes, whereas various other cell types express CXCR4 within the myocardium.
This leads to the hypothesis that the size of mediastinal lymph nodes and their respective CXCR4 PET signals correlate with the adaptive immune response to cardiac injury and might provide predictive information for functional cardiac decline during follow-up.
This prospective clinical study will use multimodal imaging to monitor chemokine receptor 4 (CXCR4) expression in the lymph nodes, myocardium, spleen, and bone marrow after acute MI. The combination of cardiac magnetic resonance (CMR), echocardiography, and positron emission tomography (PET) along with blood collection for immunophenotyping will allow to determine i) if the size of mediastinal lymph nodes and their respective PET-derived CXCR4 signals at baseline correlate with the adaptive immune response to acute cardiac injury; and ii) if they predict cardiac adverse remodelling during longitudinal follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multimodal imaging approach. This includes a CXCR4 targeted PET/CT (\[68Ga\]Pentixafor) during the acute hospital stay, and serial CMR and Echo imaging.
Diagnostic Test: Multimodality Imaging
Patients receive CXCR4-targeted PET/CT, CMR and Echo
CXCR4 PET-derived uptake after myocardial infarction
Semi-quantitative assessment of CXCR4-derived radiotracer accumulation in the myocardium, mediastinal lymph nodes, bone marrow and spleen in patients after myocardial infarction. For quantitative analysis, standardized uptake values (SUV) will be calculated in organs of interest.
Time frame: 12 months
Correlation of quantitative parameters (SUV) with peripheral lymphocytes
SUV of organs of interest are correlated to the phenotype of peripheral lymphocytes in the peripheral blood after myocardial infarction.
Time frame: 12 months
Time course of SUV after myocardial infarction
PET/CT scans for each patient will be allocated to either day 3-4 or day 5-8 after myocardial infarction. SUV of organs of interest will be correlated to time point of imaging.
Time frame: 12 months
Correlation of myocardial damage to SUV
CMR will determine the extend of myocardial damage as necrotic volume, volume of MVO and myocardial edema. These findings will be correlated to SUV.
Time frame: 12 months
Correlation of SUV with the clincial course
Myocardial function (LVEF) and scar volumes as determined by CMR will be correlated to the intital SUV in order to correlate the clinical outcome to the tracer activity.
Time frame: 12 months
Started Apr 2022 (actual). Primary completion is estimated for Dec 2025, 44 months after the start.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 44 months is above that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wuerzburg University Hospital